FDA drafts adaptive clinical trial design guidance

By Nick Taylor

- Last updated on GMT

Related tags Clinical trial

The FDA’s draft guidance on adaptive design in clinical trials is a balanced, practical publication, according to the EVP of a CRO who expects the document to generate a “robust discussion”.

Adaptive designs have been identified as methods for improving the efficiency of the clinical trial process but there are concerns that some techniques can lead to bias. These concerns were highlighted in a recent paper in the Journal of the American Medical Association​.

To help companies and regulatory agencies navigate this emerging area the US Food and Drug Administration (FDA) has drafted guidance​ which discusses the clinical, statistical and regulatory aspects of various adaptive design studies.

Speaking to Outsourcing-Pharma, Jim Higgins, executive vice president (EVP) and director of biometrics at Health Decisions, said the document is balanced and contains a lot of practical information.

This could help to reduce confusion and allow pharma and contract research organisations (CRO) to embrace certain acceptable methods. Well understood adaptive designs covered by the draft include group sequential methods, which Higgins believes are “nicely clarified​”.


Higgins explained that adaptive design is a well debated topic in the statistics and clinical research communities and he anticipates this will lead to a “robust discussion​” of the draft.

The only comment on the draft so far has come from William Rosenberger, professor and chair, department of statistics, George Mason University, Virginia, US, who said the “document is remarkably narrow for such an important topic​”.

Higgins believes the document’s scope is deliberate, with the FDA choosing to focus on the better understood basics before branching out to other areas in the future.

The comment period closes on June 1.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more